Abstract
Beta-blocker therapy is accepted to reduce perioperative cardiovascular complications. Moreover, betablockers have potentially beneficial effects other than prevention of cardiac events. In addition to reducing anesthetic and analgesic requirements during the perioperative period, beta-blockers have neuroprotective effects, possible effectiveness in the management of intraoperative awareness-induced post-traumatic stress disorder, and antinociceptive effects. Betablockers are also useful in stabilizing hemodynamics during electroconvulsive therapy, intubation and emergency periods. Physicians need to bear in mind the benefits of beta-blockers for purposes other than preventing cardiac events when applied in the perioperative period, and should be familiar with the pharmacodynamics and effective dosages of these agents.
Current Drug Targets
Title: Beta-blockers in the Perioperative Period: Are there Indications other than Prevention of Cardiac Ischemia?
Volume: 10 Issue: 9
Author(s): Y. Kadoi and S. Saito
Affiliation:
Abstract: Beta-blocker therapy is accepted to reduce perioperative cardiovascular complications. Moreover, betablockers have potentially beneficial effects other than prevention of cardiac events. In addition to reducing anesthetic and analgesic requirements during the perioperative period, beta-blockers have neuroprotective effects, possible effectiveness in the management of intraoperative awareness-induced post-traumatic stress disorder, and antinociceptive effects. Betablockers are also useful in stabilizing hemodynamics during electroconvulsive therapy, intubation and emergency periods. Physicians need to bear in mind the benefits of beta-blockers for purposes other than preventing cardiac events when applied in the perioperative period, and should be familiar with the pharmacodynamics and effective dosages of these agents.
Export Options
About this article
Cite this article as:
Kadoi Y. and Saito S., Beta-blockers in the Perioperative Period: Are there Indications other than Prevention of Cardiac Ischemia?, Current Drug Targets 2009; 10 (9) . https://dx.doi.org/10.2174/138945009789108800
DOI https://dx.doi.org/10.2174/138945009789108800 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Frequency Domain Mapping of Atrial Fibrillation - Methodology, Experimental Data and Clinical Implications
Current Cardiology Reviews Disturbed Tryptophan Metabolism in Cardiovascular Disease
Current Medicinal Chemistry Oral Antiplatelet Treatment in STEMI: Current Practice and Future Considerations
Current Pharmaceutical Design Stress Myocardial Perfusion Imaging in the Emergency Department - New Techniques for Speed and Diagnostic Accuracy
Current Cardiology Reviews Enhanced Antioxidant and Protective Activities on Retinal Ganglion Cells of Carotenoids-Overexpressing Transgenic Carrot
Current Drug Targets Identification and Treatment of Patients with Early COPD
Current Respiratory Medicine Reviews The Diagnostic and Prognostic Value of Brain Natriuretic Peptide and Aminoterminal (nt)-pro Brain Natriuretic Peptide
Current Pharmaceutical Design Functional Foods: Salient Features and Clinical Applications
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Withdrawal Notice: Management of Right Atrial Thrombus. Where is the Evidence? : A Narrative Review
Current Cardiology Reviews An Update on Natural Products with Carbonic Anhydrase Inhibitory Activity
Current Pharmaceutical Design Regular Physical Activity and Vascular Aging
Current Pharmaceutical Design Adrenomedullins: Therapeutic Potential in Cardiovascular Disease
Current Hypertension Reviews Hormone Replacement Therapy and Stroke
Current Vascular Pharmacology Heart Transplantation in Biventricular Congenital Heart Disease: Indications, Techniques, and Outcomes
Current Cardiology Reviews Molecular Genetics of Left Ventricular Dysfunction
Current Molecular Medicine Genetic Mapping of Pharmacogenetic Regulatory Variation
Current Pharmaceutical Design Editorial (Diabetes, Obesity and Vascular Disease - An Update)
Current Pharmaceutical Design Phase 4 Studies in Heart Failure - What is Done and What is Needed?
Current Cardiology Reviews Physical Activity, Insulin Action, and Diabetes Prevention and Control
Current Diabetes Reviews Nitric Oxide as a Marker for Levo-Thyroxine Therapy in Subclinical Hypothyroid Patients
Current Vascular Pharmacology